Business in Brief

No major side effects for Teva after Copaxone patent loss; Mivtach Shamir opens talks with Bright Food over possible Tnuva deal, Castro profits slump and tech shares lead TASE above 1,400 points.

Send in e-mailSend in e-mail
Teva's Copaxone

Comments